Cambridge, Massachusetts-based Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has raised $72 million for its IPO after pricing its 4.5 million shares at $16 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symbol “FULC.” Morgan Stanley, BofA Merrill Lynch and SVB Leerink are the lead underwriters. Fulcrum’s pre-IPO backers included Third Rock Ventures and Foresite Capital.
CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases, today announced the pricing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $72.0 million, before underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by the Company.
The Company’s common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol “FULC” on July 18, 2019. The offering is expected to close on July 22, 2019, subject to customary closing conditions.
Morgan Stanley, BofA Merrill Lynch and SVB Leerink are acting as joint book-running managers for the offering.
A registration statement relating to the offering of these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on July 17, 2019. The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, by visiting EDGAR on the SEC website at www.sec.gov or from: Morgan Stanley at Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; BofA Merrill Lynch, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255, or by email at email@example.com; or from SVB Leerink at SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.